

Wytske J Fokkens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504286/publications.pdf>

Version: 2024-02-01

141
papers

11,805
citations

53794

45
h-index

28297

105
g-index

149
all docs

149
docs citations

149
times ranked

8629
citing authors

#	ARTICLE	IF	CITATIONS
1	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines 2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
2	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	1.3	1,086
3	Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology, 2016, 137, 1449-1456.e4.	2.9	833
4	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, The, 2019, 394, 1638-1650.	13.7	812
5	European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement, 2012, 23, 3 p preceding table of contents, 1-298.	6.0	506
6	International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International Forum of Allergy and Rhinology, 2016, 6, S22-209.	2.8	443
7	International consensus statement on allergy and rhinology: rhinosinusitis 2021. International Forum of Allergy and Rhinology, 2021, 11, 213-739.	2.8	398
8	IL-1 β , IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nature Immunology, 2016, 17, 636-645.	14.5	397
9	Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. Journal of Allergy and Clinical Immunology, 2017, 140, 1024-1031.e14.	2.9	376
10	European position paper on rhinosinusitis and nasal polyps 2007. Rhinology Supplement, 2007, 20, 1-136.	6.0	369
11	International Forum of Allergy and Rhinology, 2016, 6, S22-209.	2.8	398
12	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
13	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, the, 2021, 9, 1141-1153.	10.7	263
14	EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2312-2319.	5.7	239
15	Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, 1608-1614.e6.	2.9	177
16	ICON: chronic rhinosinusitis. World Allergy Organization Journal, 2014, 7, 25.	3.5	157
17	Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. Journal of Allergy and Clinical Immunology, 2019, 143, 1207-1214.	2.9	152
18	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140

#	ARTICLE	IF	CITATIONS
19	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
20	Activity of Bacteriophages in Removing Biofilms of <i>Pseudomonas aeruginosa</i> Isolates from Chronic Rhinosinusitis Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 418.	3.9	132
21	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
22	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3039-3068.	5.7	127
23	Endotype-driven treatment in chronic upper airway diseases. <i>Clinical and Translational Allergy</i> , 2017, 7, 22.	3.2	117
24	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2020, 10, 1.	3.2	110
25	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
26	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
27	IL-1 β , IL-23, and TGF- β 2 drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. <i>Nature Communications</i> , 2019, 10, 2162.	12.8	95
28	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	5.7	95
29	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
30	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	5.7	83
31	EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. <i>Rhinology</i> , 2007, 45, 97-101.	1.3	80
32	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic – An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
33	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
34	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2293-2311.	5.7	76
35	Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
36	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1640-1660.	5.7	72

#	ARTICLE	IF	CITATIONS
37	Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 25.	5.3	71
38	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
39	Mobile health tools for the management of chronic respiratory diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1292-1306.	5.7	66
40	Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases. <i>Science Immunology</i> , 2021, 6, .	11.9	65
41	ARIA–EAACI statement on asthma and COVID–19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	5.7	57
42	Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. <i>International Forum of Allergy and Rhinology</i> , 2016, 6, 557-567.	2.8	55
43	<scp>ARIA</scp> pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy“. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
44	Evidence-based Surgery for Chronic Rhinosinusitis with and without Nasal Polyps. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 427.	5.3	51
45	European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). <i>Clinical and Translational Allergy</i> , 2017, 7, 49.	3.2	48
46	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
47	Real–life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 670-674.	5.7	46
48	Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment. <i>PLoS ONE</i> , 2018, 13, e0192330.	2.5	45
49	Real–life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2867-2878.	5.7	45
50	Fungus: A Role in Pathophysiology of Chronic Rhinosinusitis, Disease Modifier, A–Treatment Target, or–No Role at All?. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, 677-688.	1.9	44
51	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2511-2523.	3.8	44
52	Short–time cold dry air exposure: A useful diagnostic tool for nasal hyperresponsiveness. <i>Laryngoscope</i> , 2012, 122, 2615-2620.	2.0	40
53	Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 337-346.	10.7	40
54	Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1532-1549.e1.	3.8	38

#	ARTICLE	IF	CITATIONS
55	Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. <i>Rhinology</i> , 2016, 54, 117-128.	1.3	38
56	Role of fungi in pathogenesis of chronic rhinosinusitis. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 19-23.	1.8	36
57	Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 813-820.	2.8	33
58	Management of patients with chronic rhinosinusitis during the COVID-19 pandemic: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 677-688.	5.7	33
59	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air [®] App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
60	Challenges in the Management of Inverted Papilloma: A Review of 72 Revision Cases. <i>Laryngoscope</i> , 2016, 126, 322-328.	2.0	31
61	Capsaicin for Rhinitis. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 60.	5.3	31
62	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-EGA ² -LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
63	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air [®] . <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
64	Highlights in the advances of chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3349-3358.	5.7	27
65	High Degree of Overlap between Responses to a Virus and to the House Dust Mite Allergen in Airway Epithelial Cells. <i>PLoS ONE</i> , 2014, 9, e87768.	2.5	27
66	Histone deacetylase inhibitors up-regulate LL-37 expression independent of toll-like receptor mediated signalling in airway epithelial cells. <i>Journal of Inflammation</i> , 2013, 10, 15.	3.4	23
67	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. <i>Clinical and Translational Allergy</i> , 2015, 5, 36.	3.2	23
68	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
69	Specific Induction of TSLP by the Viral RNA Analogue Poly(I:C) in Primary Epithelial Cells Derived from Nasal Polyps. <i>PLoS ONE</i> , 2016, 11, e0152808.	2.5	22
70	Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 267-275.	2.3	21
71	Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 57-66.	1.9	21
72	EGR-1 and DUSP-1 are important negative regulators of pro-allergic responses in airway epithelium. <i>Molecular Immunology</i> , 2015, 65, 43-50.	2.2	20

#	ARTICLE	IF	CITATIONS
73	Avoid prescribing antibiotics in acute rhinosinusitis. <i>BMJ, The</i> , 2014, 349, g5703-g5703.	6.0	17
74	Endoscopic sinus surgery and musculoskeletal symptoms. <i>Rhinology</i> , 2016, 54, 105-110.	1.3	17
75	The prevalence of non-allergic rhinitis phenotypes in the general population: A cross-sectional study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2163-2174.	5.7	17
76	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air [®] real-world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
77	Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 575-585.	3.1	16
78	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
79	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
80	Direct and indirect costs of allergic and non-allergic rhinitis in the Netherlands. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2993-2996.	5.7	15
81	Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 160-168.	1.0	15
82	White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. <i>Frontiers in Allergy</i> , 2022, 3, .	2.8	15
83	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 657-669.	1.8	14
84	Endoscopic sinus surgery in adult patients with chronic rhinosinusitis with nasal polyps (PolypESS): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 39.	1.6	14
85	Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions. <i>PLoS ONE</i> , 2018, 13, e0200366.	2.5	14
86	Dietary patterns and respiratory health in adults from nine European countries Evidence from the GALEN study. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1474-1482.	2.9	14
87	Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1768-1771.	5.7	14
88	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 812-821.	5.7	14
89	Synergy between TLR-2 and TLR-3 signaling in primary human nasal epithelial cells. <i>Immunobiology</i> , 2015, 220, 445-451.	1.9	13
90	No Mucosal Atrophy and Reduced Inflammatory Cells: Active-controlled Trial with Yearlong Fluticasone Furoate Nasal Spray. <i>American Journal of Rhinology and Allergy</i> , 2012, 26, 36-44.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Dendritic Cell Subsets in Oral Mucosa of Allergic and Healthy Subjects. PLoS ONE, 2016, 11, e0154409.	2.5	11
92	The International Classification of the radiological Complexity (ICC) of frontal recess and frontal sinus. International Forum of Allergy and Rhinology, 2017, 7, 332-337.	2.8	11
93	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€™ Meeting Report (Part 1). Journal of Thoracic Disease, 2019, 11, 3633-3642.	1.4	11
94	Medical algorithms: Management of chronic rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1415-1416.	5.7	11
95	The prevalence of asthma in adult population of southwestern Iran and its association with chronic rhinosinusitis: a GA2LEN study. Clinical and Translational Allergy, 2019, 9, 43.	3.2	10
96	Rhinosinusitis in morbidity registrations in Dutch General Practice: a retro-spective case-control study. BMC Family Practice, 2015, 16, 120.	2.9	9
97	A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis. International Forum of Allergy and Rhinology, 2021, 11, 1452-1460.	2.8	9
98	Intranasal corticosteroids for non-allergic rhinitis. The Cochrane Library, 2019, 2019, .	2.8	9
99	Allergen immunotherapy in MASKâ€™air users in real-life: Results of a Bayesian mixed-effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
100	Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report. Laryngoscope, 2021, 131, 2649-2651.	2.0	8
101	Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis. World Allergy Organization Journal, 2021, 14, 100585.	3.5	8
102	Comparison of rhinitis treatments using MASKâ€™air data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
103	Novel, Alternative, and Controversial Therapies of Rhinitis. Immunology and Allergy Clinics of North America, 2016, 36, 401-423.	1.9	7
104	New delivery forms of nasal corticosteroids. Journal of Allergy and Clinical Immunology, 2019, 143, 87-88.	2.9	7
105	Phenotyping, endotyping and clinical decision-making. Rhinology, 2016, 54, 97-98.	1.3	6
106	Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients. Frontiers in Allergy, 2021, 2, 734000.	2.8	5
107	The extent of endoscopic sinus surgery in patients with severe chronic rhinosinusitis with nasal polyps (AirGOs Operative). Rhinology, 2021, 4, 154-160.	0.3	5
108	The GA2LEN Sinusitis Cohortâ€™: an introduction. Clinical and Translational Allergy, 2015, 5, O1.	3.2	4

#	ARTICLE	IF	CITATIONS
109	Novel roles for nasal epithelium in the pathogenesis of chronic rhinosinusitis with nasal polyps. <i>Rhinology</i> , 2019, 57, 0-0.	1.3	4
110	Short and long-term safety of MP29: a new therapy for the treatment of allergic rhinitis. <i>Clinical and Translational Allergy</i> , 2013, 3, O15.	3.2	3
111	Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery. <i>The Cochrane Library</i> , 2017, , .	2.8	3
112	Rhinology Future Debates 2017 by <scp>EUFOREA</scp>: Novel treatments and surgical solutions in rhinology. <i>Clinical Otolaryngology</i> , 2018, 43, 1429-1438.	1.2	3
113	Role of steroids in the treatment of rhinosinusitis with and without polyposis. <i>Clinical Allergy and Immunology</i> , 2007, 20, 241-50.	0.7	3
114	Shape of the Osseous External Auditory Canal and Its Relationship to Troublesome Cavities. <i>Laryngoscope</i> , 2016, 126, 693-698.	2.0	2
115	Outpatient therapy for nonallergic rhinitis. <i>Clinical Allergy and Immunology</i> , 2007, 19, 363-73.	0.7	2
116	In response to <i>the Effect of Topical Amphotericin B on Inflammatory Markers in Patients with Chronic Rhinosinusitis: A Multicenter Randomized Controlled Study</i>. <i>Laryngoscope</i> , 2010, 120, 213-214.	2.0	1
117	Symptoms of chronic rhinosinusitis with and without nasal polyps. <i>Clinical and Translational Allergy</i> , 2013, 3, O2.	3.2	1
118	New Findings in Nonallergic Rhinitis and Local Allergic Rhinitis. <i>Current Otorhinolaryngology Reports</i> , 2013, 1, 106-112.	0.5	1
119	Breaking nasal epithelial cell tolerance lipopolysaccharide exposure by CD16-mediated co-stimulation with human serum immunoglobulin G. <i>Clinical and Translational Allergy</i> , 2015, 5, P4.	3.2	1
120	Acute and chronic rhinosinusitis and allergic rhinitis in relation to environment, comorbidity and ethnicity. <i>Clinical and Translational Allergy</i> , 2015, 5, P26.	3.2	1
121	A new allergic rhinitis therapy (MP29) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch. <i>Clinical and Translational Allergy</i> , 2015, 5, P33.	3.2	1
122	MP29's advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis. <i>Clinical and Translational Allergy</i> , 2015, 5, P36.	3.2	1
123	A new intranasal therapy (MP29) is more effective than current firstline therapy regardless of season, symptom or severity.. <i>Clinical and Translational Allergy</i> , 2015, 5, P38.	3.2	1
124	Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease. <i>The Cochrane Library</i> , 2019, , .	2.8	1
125	Eye for an eye: near-fatal outcome of fungal infection in a young, diabetic girl. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223059.	0.5	1
126	Preface. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, xv-xvii.	1.9	0

#	ARTICLE	IF	CITATIONS
127	A new therapy (MP29â€œ02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity. <i>Clinical and Translational Allergy</i> , 2013, 3, O16.	3.2	0
128	Early growth response protein 1 and dual specificity protein phosphatase 1 are involved in downâ€œregulation of allergic responses. <i>Clinical and Translational Allergy</i> , 2013, 3, P26.	3.2	0
129	A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29â€œ02*. <i>Clinical and Translational Allergy</i> , 2013, 3, P42.	3.2	0
130	A new therapy (MP29â€œ02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis. <i>Clinical and Translational Allergy</i> , 2013, 3, P41.	3.2	0
131	A new therapy (MP29â€œ02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion. <i>Clinical and Translational Allergy</i> , 2013, 3, P39.	3.2	0
132	A new therapy (MP29â€œ02*) effectively targets the entire seasonal allergic rhinitis symptom complex. <i>Clinical and Translational Allergy</i> , 2013, 3, P45.	3.2	0
133	Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N. <i>Clinical and Translational Allergy</i> , 2015, 5, P2.	3.2	0
134	Patient reported outcome measurements in chronic rhinosinusitis; assessing the correlation between RSOMâ€œ31 and VAS.. <i>Clinical and Translational Allergy</i> , 2015, 5, P28.	3.2	0
135	A new allergic rhinitis therapy (MP29â€œ02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies. <i>Clinical and Translational Allergy</i> , 2015, 5, P34.	3.2	0
136	Identification of gaps in the current allergic rhinitis guidelines and how these can be filled. <i>Clinical and Translational Allergy</i> , 2015, 5, P39.	3.2	0
137	Guidelines in otorhinolaryngology: a critical view. <i>Brazilian Journal of Otorhinolaryngology</i> , 2015, 81, 345-346.	1.0	0
138	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 350.	2.9	0
139	Legends of allergy and immunology: Niels Mygind. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3839-3840.	5.7	0
140	Combined medical and surgical therapy for chronic rhinosinusitis with nasal polyposis â€œ Authors' reply. <i>Lancet Respiratory Medicine</i> , 2022, 10, e39.	10.7	0
141	Migration and allergic diseases: Findings from a populationâ€œbased study in adults in Amsterdam, the Netherlands. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3667-3670.	5.7	0